Ascletis Pharma Inc
HKEX:1672
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.78
1.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ascletis Pharma Inc
Ascletis Pharma Inc
Total Current Liabilities
Ascletis Pharma Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ascletis Pharma Inc
HKEX:1672
|
Total Current Liabilities
¥140.7m
|
CAGR 3-Years
24%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Current Liabilities
¥12.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Current Liabilities
¥1.4B
|
CAGR 3-Years
100%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Current Liabilities
¥2.7B
|
CAGR 3-Years
48%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Current Liabilities
¥1.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
41%
|
CAGR 10-Years
32%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Current Liabilities
¥22.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
32%
|
CAGR 10-Years
71%
|
|
Ascletis Pharma Inc
Glance View
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
See Also
What is Ascletis Pharma Inc's Total Current Liabilities?
Total Current Liabilities
140.7m
CNY
Based on the financial report for Dec 31, 2023, Ascletis Pharma Inc's Total Current Liabilities amounts to 140.7m CNY.
What is Ascletis Pharma Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
9%
Over the last year, the Total Current Liabilities growth was 30%. The average annual Total Current Liabilities growth rates for Ascletis Pharma Inc have been 24% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
